CN115023418B - 用于癌症治疗的双氨基喹啉和纳米制剂 - Google Patents

用于癌症治疗的双氨基喹啉和纳米制剂 Download PDF

Info

Publication number
CN115023418B
CN115023418B CN202080080553.6A CN202080080553A CN115023418B CN 115023418 B CN115023418 B CN 115023418B CN 202080080553 A CN202080080553 A CN 202080080553A CN 115023418 B CN115023418 B CN 115023418B
Authority
CN
China
Prior art keywords
inhibitor
cancer
nanocarrier
baq
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080080553.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN115023418A (zh
Inventor
李源培
马朝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Priority to CN202411558409.5A priority Critical patent/CN119591543A/zh
Publication of CN115023418A publication Critical patent/CN115023418A/zh
Application granted granted Critical
Publication of CN115023418B publication Critical patent/CN115023418B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/032—Transmission computed tomography [CT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080080553.6A 2019-09-18 2020-09-18 用于癌症治疗的双氨基喹啉和纳米制剂 Active CN115023418B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411558409.5A CN119591543A (zh) 2019-09-18 2020-09-18 用于癌症治疗的双氨基喹啉和纳米制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902156P 2019-09-18 2019-09-18
US62/902,156 2019-09-18
PCT/US2020/051430 WO2021055705A1 (en) 2019-09-18 2020-09-18 Biaminoquinolines and nanoformulations for cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411558409.5A Division CN119591543A (zh) 2019-09-18 2020-09-18 用于癌症治疗的双氨基喹啉和纳米制剂

Publications (2)

Publication Number Publication Date
CN115023418A CN115023418A (zh) 2022-09-06
CN115023418B true CN115023418B (zh) 2024-11-19

Family

ID=74884705

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080080553.6A Active CN115023418B (zh) 2019-09-18 2020-09-18 用于癌症治疗的双氨基喹啉和纳米制剂
CN202411558409.5A Pending CN119591543A (zh) 2019-09-18 2020-09-18 用于癌症治疗的双氨基喹啉和纳米制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411558409.5A Pending CN119591543A (zh) 2019-09-18 2020-09-18 用于癌症治疗的双氨基喹啉和纳米制剂

Country Status (6)

Country Link
US (1) US20230348419A1 (enExample)
EP (1) EP4031543A4 (enExample)
JP (2) JP7652434B2 (enExample)
CN (2) CN115023418B (enExample)
CA (1) CA3154678A1 (enExample)
WO (1) WO2021055705A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020012066A (es) 2018-05-14 2021-04-28 Nuvation Bio Inc Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114948938B (zh) * 2022-02-22 2023-08-11 江苏省中医院 白术内酯i在制备预防和/或治疗宫颈癌的药物中的用途
CN114948901B (zh) * 2022-05-06 2023-04-21 郑州大学第一附属医院 一种协同治疗乳腺癌的依西美坦纳米粒、制剂及其制备方法
CN116059172B (zh) * 2023-02-01 2025-05-13 中山大学附属第八医院（深圳福田） 一种纳米递药系统及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687853A (zh) * 2011-04-29 2014-03-26 宾夕法尼亚大学托管会 新型双氨基喹啉化合物及其制备的药物组合物和它们的用途
WO2016022956A1 (en) * 2014-08-08 2016-02-11 The Trustees Of The University Of Pennsylvania Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
WO2016196393A2 (en) * 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183413B2 (en) * 2003-04-11 2007-02-27 Taigen Biotechnology Aminoquinoline compounds
US20130011448A1 (en) * 2010-03-16 2013-01-10 Ge Healthcare Bio-Sciences Ab System for improved delivery of gene modulating compounds
WO2015068142A2 (en) * 2013-11-11 2015-05-14 Cellworks Group, Inc. Compositions, process of preparation of said compositions, uses and method of management of myeloproliferative disorder
US10774047B2 (en) * 2015-04-17 2020-09-15 The Trustees Of The University Of Pennsylvania Dimeric quinacrine derivatives as autophagy inhibitors for cancer therapy
US20180280372A1 (en) * 2016-11-22 2018-10-04 Washington University Compositions and methods for inhibiting autophagy and contraception

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103687853A (zh) * 2011-04-29 2014-03-26 宾夕法尼亚大学托管会 新型双氨基喹啉化合物及其制备的药物组合物和它们的用途
WO2016022956A1 (en) * 2014-08-08 2016-02-11 The Trustees Of The University Of Pennsylvania Asymmetric bisaminoquinolines and bisaminoquinolines with varied linkers as autophagy inhibitors for cancer and other therapy
WO2016196393A2 (en) * 2015-05-29 2016-12-08 Presage Biosciences, Inc. Autophagy-inhibiting compounds and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"A pH-Driven Small-Molecule Nanotransformer Hijacks Lysosomes and Overcomes Autophagy-Induced Resistance in Cancer";Zhao Ma等;《Angew. Chem. Int. Ed. 》;第61卷;第1-11页 *
"Anticancer properties of bisaminoquinolines with modified linkers";Yuanhao Wang等;《Bioorg. Med. Chem. Lett. 》;第49卷;第1-6页 *
"Pharmacophore hybridisation and nanoscale assembly to discover self-delivering lysosomotropic new-chemical entities for cancer therapy";Zhao Ma等;《NATURE COMMUNICATIONS》;第11卷;第4615-4626页 *
RN：1349611-33-1;REGISTRY;《RN：1349611-33-1》;第1页 *

Also Published As

Publication number Publication date
US20230348419A1 (en) 2023-11-02
WO2021055705A1 (en) 2021-03-25
JP2025094953A (ja) 2025-06-25
CN119591543A (zh) 2025-03-11
JP7652434B2 (ja) 2025-03-27
JP2022549169A (ja) 2022-11-24
CA3154678A1 (en) 2021-03-25
EP4031543A4 (en) 2023-09-27
EP4031543A1 (en) 2022-07-27
CN115023418A (zh) 2022-09-06

Similar Documents

Publication Publication Date Title
CN115023418B (zh) 用于癌症治疗的双氨基喹啉和纳米制剂
US10960078B2 (en) Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof
US20220096640A1 (en) Hsp90-targeting conjugates and formulations thereof
US20210000966A1 (en) Hsp90-targeting conjugates and formulations thereof
EP3388055A1 (en) Method for preparing liposome
AU2020384481B2 (en) Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
CN117157281A (zh) 1,2,4,5-四噁烷化合物的靶向递送及其用途
KR20230033075A (ko) 초음파 감응성 폴리머좀 및 이의 제조방법
AU2018202949B2 (en) Bolaamphiphilic compounds, compositions and uses thereof
KR20230161891A (ko) 리포좀 및 이를 포함하는 약학 조성물
TW202341977A (zh) 用於預防與治療腦癌或轉移性腦癌的藥物裝載的介孔二氧化矽奈米粒子
Wang et al. Bench-to-bedside translation of podophyllotoxin-based nanomedicines for cancer treatment: Utopias and reality?
US20250269031A1 (en) Mitochondria targeting quinolinium-drug conjugates and their self-assembling nanoformulations for cancer therapy
KR20230158044A (ko) 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
CN121181607A (zh) 一种用于治疗儿童实体瘤的药物
WO2020056205A1 (en) Hsp90-targeting conjugates and formulations thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant